(VIANEWS) – M.D.C. Holdings (MDC), Physicians Realty Trust (DOC), Genmab (GMAB) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. M.D.C. Holdings (MDC)
45.5% sales growth and 12.4% return on equity
M.D.C. Holdings, Inc., through its subsidiaries, engages in the homebuilding and financial service businesses. Its homebuilding operations include purchasing finished lots or developing lots for the construction and sale primarily of single-family detached homes to first-time and first-time move-up homebuyers under the Richmond American Homes name. The company conducts its homebuilding operations in Arizona, California, Nevada, Washington, Oregon, Colorado, Utah, Virginia, Maryland, and Florida. Its financial services operations comprise originating mortgage loans primarily for homebuyers; providing insurance coverage primarily to its homebuilding subsidiaries and subcontractors for homes sold by its homebuilding subsidiaries, and for work performed in completed subdivisions; acting as a re-insurer on the claims; selling third-party personal property and casualty insurance products to homebuyers; and offering title agency services to homebuilding subsidiaries and customers in Colorado, Florida, Maryland, Nevada, and Virginia. The company was founded in 1972 and is headquartered in Denver, Colorado.
Earnings Per Share
As for profitability, M.D.C. Holdings has a trailing twelve months EPS of $5.29.
PE Ratio
M.D.C. Holdings has a trailing twelve months price to earnings ratio of 11.88. Meaning, the purchaser of the share is investing $11.88 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.4%.
Volume
Today’s last reported volume for M.D.C. Holdings is 2417080 which is 27.56% above its average volume of 1894850.
Moving Average
M.D.C. Holdings’s worth is above its 50-day moving average of $62.64 and way above its 200-day moving average of $50.65.
2. Physicians Realty Trust (DOC)
27.1% sales growth and 4.71% return on equity
Physicians Realty Trust is a self-managed healthcare real estate company organized to acquire, selectively develop, own and manage healthcare properties that are leased to physicians, hospitals and healthcare delivery systems. The Company invests in real estate that is integral to providing high quality healthcare. The Company conducts its business through an UPREIT structure in which its properties are owned by Physicians Realty L.P., a Delaware limited partnership (the “operating partnership”), directly or through limited partnerships, limited liability companies or other subsidiaries. The Company is the sole general partner of the operating partnership and, as of September 30, 2020, owned approximately 97.4% of OP Units.
Earnings Per Share
As for profitability, Physicians Realty Trust has a trailing twelve months EPS of $0.56.
PE Ratio
Physicians Realty Trust has a trailing twelve months price to earnings ratio of 32.82. Meaning, the purchaser of the share is investing $32.82 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.71%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.6%, now sitting on 2.18B for the twelve trailing months.
3. Genmab (GMAB)
17.9% sales growth and 14.78% return on equity
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Earnings Per Share
As for profitability, Genmab has a trailing twelve months EPS of $0.96.
PE Ratio
Genmab has a trailing twelve months price to earnings ratio of 30.48. Meaning, the purchaser of the share is investing $30.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.78%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 4800% and 1183.3%, respectively.
Yearly Top and Bottom Value
Genmab’s stock is valued at $29.26 at 01:22 EST, way below its 52-week high of $42.99 and way above its 52-week low of $26.32.
Moving Average
Genmab’s value is under its 50-day moving average of $29.26 and way under its 200-day moving average of $33.99.
4. NAPCO Security Technologies (NSSC)
12.9% sales growth and 30.06% return on equity
Napco Security Technologies, Inc. develops, manufactures, and sells security products in the United States and internationally. The company offers access control systems, door-locking products, intrusion and fire alarm systems, and video surveillance systems for commercial, residential, institutional, industrial, and governmental applications. Its access control systems include various types of identification readers, control panels, PC-based computers, and electronically activated door-locking devices; and door locking devices comprise microprocessor-based electronic door locks with push button, card readers and bio-metric operation, door alarms, mechanical door locks, and simple dead bolt locks. The company's alarm systems include automatic communicators, cellular communication devices, control panels, combination control panels/digital communicators and digital keypad systems, fire alarm control panels, and area detectors; and video surveillance systems comprise video cameras, control panels, video monitors, or PCs. It also buys and resells various identification readers, video cameras, PC-based computers, and peripheral equipment for access control and video surveillance systems; offers school security products; and markets peripheral and related equipment manufactured by other companies. The company markets and sells its products primarily to independent distributors, dealers, and installers of security equipment. Napco Security Technologies, Inc. was founded in 1969 and is headquartered in Amityville, New York.
Earnings Per Share
As for profitability, NAPCO Security Technologies has a trailing twelve months EPS of $1.16.
PE Ratio
NAPCO Security Technologies has a trailing twelve months price to earnings ratio of 33.72. Meaning, the purchaser of the share is investing $33.72 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 30.06%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
NAPCO Security Technologies’s EBITDA is 82.92.
5. Watts Water Technologies (WTS)
11.2% sales growth and 18.63% return on equity
Watts Water Technologies, Inc. supplies products and solutions that manage and conserve the flow of fluids and energy into, through, and out of buildings in the commercial, industrial, and residential markets in the Americas, Europe, the Asia-Pacific, the Middle East, and Africa. The company offers residential and commercial flow control and protection products, including backflow preventers, water pressure regulators, temperature and pressure relief valves, thermostatic mixing valves, and leak detection and protection products for plumbing and hot water applications. It also provides heating, ventilation, and air conditioning and gas products comprising commercial boilers, and water heaters and heating solutions; hydronic and electric heating systems for under-floor radiant applications; custom heat and hot water solutions; hydronic pump groups for boiler manufacturers and alternative energy control packages; and flexible stainless steel connectors for natural and liquid propane gas in commercial food service and residential applications. In addition, the company offers drainage and water re-use products, such as drainage products and engineered rain water harvesting solutions for commercial, industrial, marine, and residential applications; and water quality products that include point-of-use and point-of-entry water filtration, conditioning, and scale prevention systems for commercial, marine, and residential applications. The company sells its products to plumbing, heating, and mechanical wholesale distributors and dealers, as well as original equipment manufacturers, specialty product distributors, and do-it-yourself and retail chains; and wholesalers and private label accounts. Watts Water Technologies, Inc. was founded in 1874 and is headquartered in North Andover, Massachusetts.
Earnings Per Share
As for profitability, Watts Water Technologies has a trailing twelve months EPS of $7.81.
PE Ratio
Watts Water Technologies has a trailing twelve months price to earnings ratio of 26.39. Meaning, the purchaser of the share is investing $26.39 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.63%.
6. PayPal (PYPL)
7% sales growth and 20.55% return on equity
PayPal Holdings, Inc. operates a technology platform that enables digital payments on behalf of merchants and consumers worldwide. It operates a two-sided network at scale that connects merchants and consumers that enables its customers to connect, transact, and send and receive payments through online and in person, as well as transfer and withdraw funds using various funding sources, such as bank accounts, PayPal or Venmo account balance, PayPal and Venmo branded credit products comprising its installment products, credit and debit cards, and cryptocurrencies, as well as other stored value products, including gift cards and eligible rewards. The company provides payment solutions under the PayPal, PayPal Credit, Braintree, Venmo, Xoom, Zettle, Hyperwallet, Honey, and Paidy names. The company was founded in 1998 and is headquartered in San Jose, California.
Earnings Per Share
As for profitability, PayPal has a trailing twelve months EPS of $3.84.
PE Ratio
PayPal has a trailing twelve months price to earnings ratio of 16.82. Meaning, the purchaser of the share is investing $16.82 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.55%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
PayPal’s EBITDA is 1.98.
Yearly Top and Bottom Value
PayPal’s stock is valued at $64.59 at 01:22 EST, way below its 52-week high of $77.95 and way above its 52-week low of $50.25.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.7%, now sitting on 29.77B for the twelve trailing months.
7. Grand Canyon Education (LOPE)
6% sales growth and 30.24% return on equity
Grand Canyon Education, Inc. provides education services to colleges and universities in the United States. The company's technology services include learning management system, internal administration, infrastructure, and support services; academic services comprises program and curriculum, faculty and related training and development, class scheduling, and skills and simulation lab sites; and counseling services and support include admission, financial aid, and field experience and other counseling services. It also offers marketing and communication services, such as lead acquisition, digital communications strategy, brand identity, market research, media planning and strategy, video, and business intelligence and data science; and back-office services comprising finance and accounting, human resources, audit, and procurement services. The company supports healthcare education programs for 27 universities. Grand Canyon Education, Inc. was founded in 1949 and is based in Phoenix, Arizona.
Earnings Per Share
As for profitability, Grand Canyon Education has a trailing twelve months EPS of $6.8.
PE Ratio
Grand Canyon Education has a trailing twelve months price to earnings ratio of 19.44. Meaning, the purchaser of the share is investing $19.44 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 30.24%.
